<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>5HT1-receptor Agonists: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i572.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i572.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i572.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i582.htm" title="Previous: Toremifene">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i965.htm" title="Next: Frovatriptan">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i572">5HT<sub>1</sub>-receptor Agonists</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>5HT<sub>1</sub>-receptor Agonists</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i233.htm" name="_233">Citalopram</a></td><td class="cBV"><b>increased risk of CNS toxicity when  5HT<sub>1</sub> agonists given with citalopram (manufacturer of citalopram advises avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1024.htm" name="_1024">Duloxetine</a></td><td>possible increased serotonergic effects when  5HT<sub>1</sub> agonists given with duloxetine </td><td></td></tr><tr><td><a href="41001i687.htm" name="_687">Selegiline</a></td><td>avoidance of  5HT<sub>1</sub> agonists advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>increased serotonergic effects when  5HT<sub>1</sub> agonists given with St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>possible increased serotonergic effects when  5HT<sub>1</sub> agonists given with venlafaxine </td><td></td></tr></tbody></table><p><b>Frovatriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  frovatriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 24 hours after frovatriptan, avoid frovatriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>metabolism of  frovatriptan inhibited by fluvoxamine </td><td></td></tr></tbody></table><p><b>Eletriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by clarithromycin (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  eletriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 24 hours after eletriptan, avoid eletriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by erythromycin (risk of toxicity)—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by indinavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by itraconazole (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by ketoconazole (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by nelfinavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  eletriptan increased by ritonavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Almotriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  almotriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 6 hours after almotriptan, avoid almotriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  almotriptan increased by ketoconazole (increased risk of toxicity)</td><td></td></tr></tbody></table><p><b>Naratriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td>possible increased serotonergic effects when  naratriptan given with SSRIs </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  naratriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 24 hours after naratriptan, avoid naratriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr></tbody></table><p><b>Rizatriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  rizatriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 6 hours after rizatriptan, avoid rizatriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>risk of CNS toxicity when  rizatriptan given with MAOIs (avoid rizatriptan for 2 weeks after MAOIs)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>risk of CNS toxicity when  rizatriptan given with moclobemide (avoid rizatriptan for 2 weeks after moclobemide)</b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td>plasma concentration of  rizatriptan increased by propranolol (manufacturer of rizatriptan advises halve dose and avoid within 2 hours of propranolol)</td><td></td></tr></tbody></table><p><b>Sumatriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i233.htm">Citalopram</a></td><td class="cBV"><b>increased risk of CNS toxicity when  sumatriptan given with citalopram </b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  sumatriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 6 hours after sumatriptan, avoid sumatriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i964.htm">Escitalopram</a></td><td class="cBV"><b>increased risk of CNS toxicity when  sumatriptan given with escitalopram </b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>increased risk of CNS toxicity when  sumatriptan given with fluoxetine </b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>increased risk of CNS toxicity when  sumatriptan given with fluvoxamine </b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>possible risk of toxicity when  sumatriptan given with lithium </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>risk of CNS toxicity when  sumatriptan given with MAOIs (avoid sumatriptan for 2 weeks after MAOIs)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>risk of CNS toxicity when  sumatriptan given with moclobemide (avoid sumatriptan for 2 weeks after moclobemide)</b></td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td class="cBV"><b>increased risk of CNS toxicity when  sumatriptan given with paroxetine </b></td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td>CNS toxicity reported when  sumatriptan given with sertraline </td><td></td></tr></tbody></table><p><b>Zolmitriptan</b> belongs to
      <b>5HT<sub>1</sub>-receptor Agonists</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  zolmitriptan inhibited by cimetidine (reduce dose of zolmitriptan)</td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of vasospasm when  zolmitriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 6 hours after zolmitriptan, avoid zolmitriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>metabolism of  zolmitriptan possibly inhibited by fluvoxamine (reduce dose of zolmitriptan)</td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>increased risk of CNS toxicity when  zolmitriptan given with MAOIs </b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>risk of CNS toxicity when  zolmitriptan given with moclobemide (reduce dose of zolmitriptan)</b></td><td></td></tr><tr><td><a href="41001i193.htm">Quinolones</a></td><td>metabolism of  zolmitriptan possibly inhibited by quinolones (reduce dose of zolmitriptan)</td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i965.htm" title="Frovatriptan">Frovatriptan</a></li><li><a href="41001i963.htm" title="Eletriptan">Eletriptan</a></li><li><a href="41001i925.htm" title="Almotriptan">Almotriptan</a></li><li><a href="41001i573.htm" title="Naratriptan">Naratriptan</a></li><li><a href="41001i862.htm" title="Rizatriptan">Rizatriptan</a></li><li><a href="41001i574.htm" title="Sumatriptan">Sumatriptan</a></li><li><a href="41001i575.htm" title="Zolmitriptan">Zolmitriptan</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i582.htm">Previous: Toremifene</a> | <a class="top" href="41001i572.htm#">Top</a> | <a accesskey="]" href="41001i965.htm">Next: Frovatriptan</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>